[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminium in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in their Infants

What is the purpose of the study?

The main purpose of this study is to determine if giving the RSV F vaccine (against Respiratory Syncytial Virus) during the last trimester of pregnancy can prevent severe lung disease caused by RSV in their infants.

Upstate Institutional Review Board (IRB) Number:

915692

Study Phase:

Phase III

Patient Age Group:

Children

Principal Investigator:

Joseph B Domachowske

Who can I contact for more information?

Name: Lori J Ferguson
Phone: 315-464-6331
Email: ferguslo@upstate.edu

Return to Previous Page || Search Again

Top